Since there is currently no drug that can directly inhibit the deregulated eIF4F complex in cancer cells, we assessed the effect of the next generation dual mTOR inhibitor CC214-1 on the translation initiation complex downstream of mTOR. This evidence concerns the gene EIF4E and cancer.